Cargando…
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
CRISPR Cas9-based screening is a powerful approach for identifying and characterizing novel drug targets. Here, we elucidate the synthetic lethal mechanism of deubiquitinating enzyme USP1 in cancers with underlying DNA damage vulnerabilities, specifically BRCA1/2 mutant tumors and a subset of BRCA1/...
Autores principales: | Simoneau, Antoine, Engel, Justin L., Bandi, Madhavi, Lazarides, Katherine, Liu, Shangtao, Meier, Samuel R., Choi, Ashley H., Zhang, Hongxiang, Shen, Binzhang, Martires, Lauren, Gotur, Deepali, Pham, Truc V., Li, Fang, Gu, Lina, Gong, Shanzhong, Zhang, Minjie, Wilker, Erik, Pan, Xuewen, Whittington, Douglas A., Throner, Scott, Maxwell, John P., Chen, Yingnan, Yu, Yi, Huang, Alan, Andersen, Jannik N., Feng, Tianshu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891357/ https://www.ncbi.nlm.nih.gov/pubmed/36228090 http://dx.doi.org/10.1158/1535-7163.MCT-22-0409 |
Ejemplares similares
-
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011) -
Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011) -
Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011) -
Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010) -
Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)